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showed a dominance profile in 84% and 90% of all simulations.CONCLUSIONS:The
early use of Sevelamer in NDD-CKD patients proved more effective and less costly,
generating good value for money from the NHS perspective.
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OBJECTIVES: There are numerous publications on the effects of Ketosteril (a keto-
acid-aminoacid oral preparate) both in predialysis and dialysis patients. No data
exists, however, to the authors’ knowledge regarding its pharmacoeconomic im-
pact on the treatment of predialysis patients. Our aim was to evaluate the cost-
effectiveness of Ketodiet (low/very low protein diet plus Ketosteril) started in stage
3 (GFR 60-30 ml/min) of chronic kidney disease (CKD) versus starting it in stage 4
(GFR 30-15 ml/min) of CKD. A simulation model has been developed to compare the
relative costs and health-benefits of the two alternatives. METHODS: Therapeuti-
cally effectiveness was clarified on published Hungarian Ketosteril studies (n171).
GFR progression was estimated with a mixed (fixed and random effect) regression
analysis of the data for patients treated with and without early Ketosteril for de-
terministic modeling. 1000 hypothetical patient curves were generated using
Bayesian approach to assure the validity of our preliminary hypothesis regarding
the expected time to dialysis. Cost analysis based on 80 recent Hungarian CKD
patients’ multicenter (n9) financial resource utilization data. Quality-adjusted life
year (QALY) values were assigned to the CKD stages to assess the qualitative and
quantitative impact of the two different Ketodiet approaches. A deterministic and
probabilistic model was developed for cost-effectiveness analysis. During lifelong
modeling costs and outcomes were discounted with official Hungarian rate of 5%.
RESULTS: Deterministic modeling showed a cost favour of 6 543,48 € with early
(CKD 3) Ketodiet start. Early initiation proved to be also more effective (avg. differ-
ence: 0,71 QALY). ICER of the deterministic model (-9 216,17 €/QALY) and 76% of
cases in the probabilistic analysis resulted in a dominance with this approach.
CONCLUSIONS: Early initiation of the Ketodiet in stage 3 CKD proved to be more
advantageous in terms of both health care costs and outcomes than starting the
treatment in stage 4 CKD.
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OBJECTIVES: To perform economic evaluation of pazopanib in comparison with
sunitinib, sorafenib and bevacizumab  interferon -2a for patients with meta-
static renal cell carcinoma (mRCC).METHODS: Indirect comparison was performed
to assess the relative efficacy of studied drugs. Pazopanib was compared with
sunitinib and bevacizumab  interferon -2a in the first-line treatment and with
sorafenib in the second-line treatment of patients with mRCC. The probability of
progression-free survival (PFS) was the criteria of clinical efficacy. Costs of drugs
were calculated based on data about the prices of public purchases. Cost-minimi-
zation analysis was performed. One-way sensitivity analysis was made to assess
the impact of prices’ variations (minimal – maximal price range) on the results.
RESULTS: Indirect comparison showed no statistically significant differences in
PFS between compared drugs. The rate of severe adverse events was low for all
drugs and should not affect the costs. The cost-minimization difference for pazo-
panib was —371.44 thousands rub (—11.09 thousands $) in comparison with
sorafenib, —660. 12 thousands rub (—19.70 thousands $) in comparison with
sunitinib and —1.98 millions rub (—59.20 thousands $) in comparison with bevaci-
zumab  interferon -2a per patient. The sensitivity analysis showed that varia-
tions in prices do not affect the results and pazopanib remains a cost-saving
option. CONCLUSIONS: Pazopanib is more efficient alternative in comparison with
sunitinib, sorafenib and bevacizumab  interferon -2a for patients with mRCC.
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OBJECTIVES: Neither national nor international clinical guidelines do consistently
recommend treating non-diabetic proteinuric patients with advanced renal dis-
ease with an angiotensin-converting enzyme (ACE) inhibitor. The aim of our study
was to determine the cost-effectiveness of ACE inhibitor therapy in non-diabetic
proteinuric patients with advanced renal disease in the Netherlands. METHODS:
Two strategies were compared: treating patients with advanced renal disease with
an ACE inhibitor and no ACE inhibitor treatment. A lifetime Markov decision model
was developed using published data on costs and health outcomes and simulating
the progression of renal disease. A health care perspective was adopted. RESULTS:
In the base-case analysis, ACE inhibitor treatment is associated with lower costs
and higher benefit and therefore dominates the no-treatment strategy. A probabi-
listic sensitivity analysis shows that the probability of savings is 83%.
CONCLUSIONS: ACE inhibitor treatment for non-diabetic patients with advanced
renal disease in the Netherlands is highly cost-effective. Savings would be even
larger if prevention of cardiovascular events were considered.
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OBJECTIVES: Treatment persistence to pharmacological OAB treatment is known
to be low and may vary by type of antimuscarinic used. The aim of this study was
to estimate treatment persistence associated with fesoterodine, solifenacin or tolt-
erodine in routine clinical practice in Spain. METHODS: A retrospective study was
conducted using Primary Care electronic medical records from three towns in
Spain. Records from patients who newly initiated OAB treatment between January
2008 and December 2010, with at least 52 weeks of follow-up, were retained. Male
and female patients, over 18, with a diagnosis of OAB [ICD-9-CM 596.51], and a new
prescription of fesoterodine, tolterodine or solifenacin were included in this anal-
ysis. Pattern of treatment persistence was assessed using a Cox-proportional haz-
ard regression model and binary logistic regression adjusting for study location,
age, sex, medication possession ratio, co-morbidity burden and time since
diagnosis. RESULTS:A total of 1971 records (58.3% women, mean age 70.1 [SD:10.6])
were analyzed; 302 treated with fesoterodine, 952 with solifenacin and 717 with
tolterodine. Unadjusted mean treatment duration was 31.5 (17.6) weeks for fesot-
erodine, 29.9 (21.4) for solifenacin, and 29.0 (21.6) for tolterodine, p0.217. Cumu-
lative adjusted likelihood of discontinuation at 52 weeks was on average 22%
higher for solifenacin [Hazard Ratio 1.22 (1.03;1.44); p0.020] and 25% higher for
tolterodine [HR 1.25 (1.05;1.49); p0.014] than fesoterodine. At week 52, 37.1% of
fesoterodine-treated patients remained on initial therapy versus 33.1% solifena-
cin-treated [adjusted OR0.77 (0.58;1.03), p0.078] and 32.1% tolterodine-treated
[adjusted OR0.75 (0.55;1.03),p0.075] patients. CONCLUSIONS: Cumulative like-
lihood of discontinuating new antimuscarinic treatment for OAB over a 52-week
was significantly higher for solifenacin or tolterodine compared to fesoterodine in
Spanish clinical practice, yielding to a trend toward higher persistent rates at 52
weeks for fesoterodine.
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OBJECTIVES: Lower urinary tract symptoms (LUTS) due to Benign Prostatic Hyper-
plasia (BPH) are very common in men over age 50. BPH treatments allow the im-
provement of LUTS, the reduction of risk of acute urinary retention (AUR) and
BPH-related surgery. However, some LUTS treatments have adverse events that
can lead to poor adherence to BPH medications. It is therefore critical to monitor
adherence and facilitate communication between patients and clinicians in clini-
cal practice. The objective was to develop a scale to evaluate patient adherence and
help clinicians in the management of BPH patients.METHODS: Patient exploratory
interviews were conducted by a health psychologist among 15 men with BPH,
following a non-directive technique so that concepts were mentioned spontane-
ously by patients. The numerous concepts identified were discussed with experts
and relevant concepts for adherence were organised into a conceptual model.
RESULTS: The conceptual model included various factors linked to adherence:
patient characteristics, disease and therapy-related factors, patients’ experiences,
knowledge, beliefs, concerns and motivations, expectations, acceptance, inten-
tions, patients’ behaviours and attitudes and environmental factors. Items were
then generated for each relevant concept using patients’ own words. The scale
contains 53 items and is being tested for relevance and comprehension.
CONCLUSIONS:This scale aims to encourage patients to ask questions and express
any doubt or concerns they may have about treatment, and help clinicians identify
patients facing adherence issues. It will enable the clinicians to monitor treatment
acceptance and adherence to prescribed treatment. A future pilot study with 10
clinicians and 30 BPH patients is planned in real conditions of use to assess if the
scale will be well accepted by both clinicians and patients in clinical practice. A
validation study will then be undertaken to validate psychometric properties and
scoring of the scale, and to evaluate the ability of the score to predict adherence and
persistence.
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OBJECTIVES: Due to its longer half-life, darbepoetin alfa (DA) is administered at
extended dosing intervals compared to epoetin alfa (EPO). The aim of this study
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